Lubov Borisovna Brzhezinskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lubov Borisovna Brzhezinskaya has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Elena Valentinovna Kiseleva
Russian Medical Academy of Continuous Professional Education
2 shared publications - Elvira P. Kasatkina
Russian Medical Academy of Continuous Professional Education
2 shared publications - Goar Feliksovna Okminyan
Russian Medical Academy of Continuous Professional Education
2 shared publications - Lubov Nikolaevna Samsonova
Russian Medical Academy of Continuous Professional Education
2 shared publications - Mikhail Ivanovich Pykov
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
2 shared publications - Oleg Yu. Latyshev
Russian Medical Academy of Continuous Professional Education
2 shared publications
Latest Publications
- 15 December 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (6)
Guidelines for Practitioners: Duchenne Muscular Dystrophy (DMD). Becker Muscular Dystrophy (BMD). Early diagnosis. Therapy with the use of drugs that are currently not registered properly in Russia/by the Ministry of Healthcare of Russia
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.
- 15 December 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (6)
Guidelines for Practitioners: Duchenne Muscular Dystrophy (DMD). Becker Muscular Dystrophy (BMD). Early diagnosis. Therapy with the use of drugs that are currently not registered properly in Russia/by the Ministry of Healthcare of Russia
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.
- Open Access
- 6 February 2020
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 65 (6) , 417-424
The differential diagnosis of constitutional delay of puberty and hypogonadotropic hypogonadism in boys
Backgraund: The problem of differential diagnosis of constitutional delay of puberty/CPD and hypogonadotropic hypogonadism/HH in boys is discussed, as boys have similar genetic mechanisms and appearance. Aims: to determine accuracy of the criteria for the differential diagnosis of CDP and HH. Materials: The study included 56 boys14,40,7 years old with delayed puberty (G1P1-3/testicular volume 3сm3). We excluded patients with hypergonadotropic hypogonadism, treated with sex steroids or gonadotropins for 12 months, with endocrine/somatic diseases affecting puberty. At the first visit, we evaluated anthropometric data, bone age, testicular volume, hormones and the results of the gonadotropin-releasing hormone test/GnRH agonist test and the human chorionic gonadotropin test/hCG test. The HH was defined by a testicular volume 3сm3 after 2 years follow-up. The patients were divided into two groups: the first group with CDP and testicles 3cm3 (n=50) and the second group with HH and testicles 3cm3 (n=6). Results: At the first visit in boys with CDP corrected target height was less (Me SDS -1,8 vs -0,4, р=0,02), bone age was less (Ме SDS -2,5 vs - 0,2 р=0,03), testicular volume was more (Ме 1,9 vs 0,5, p=0,0003), hormones were significantly higher, such as, LH (Ме 1,1 vs 0,1mIU/ml, p=0,0002), FSH (Ме 1,9 vs 0,2IU/l, p=0,00007), inhibinB (Ме 142,3 vs 31,3pg/ml, p=0,00009), maxLH (Ме 18,9 vs 0,6mIU/ml, p=0,00007), maxLH/FSH (Ме 2,3 vs 0,4, p=0,0002) on the GnRH agonist test and testosterone (Ме 14,4 vs 1,1nmol/l, p=0,0001) on the hCG test than in boys with HH. The LH 0,3 mIU/ml had 86% sensitivity, 100% specificity; maxLH/FSH1- 92% sensitivity, 100% specificity; testosterone 2,7 nmol/l on the hCG test - 98% sensitivity, 100% specificity for differential diagnosis of CDP and HH in boys. However, maxLH 3,5 mIU/ml on the GnRH agonist test, FSH 0,5 IU/l, inhibinB 58 pg/ml had 100% sensitivity and specificity for diagnosis of CDP. Conclusions: The inhibinB 58 pg/ml, LH 0,3 mIU/ml, FSH 0,5 IU/l or maxLH 3,5 mIU/ml, maxLH/FSH 1,0 on the GnRH agonist test, testosterone 2,7 nmol/l on the hCG test have an excellent accuracy for the differential diagnosis of CDP and HH in prepubertal boys with delayed puberty.
- 6 February 2020
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 65 (6) , 417-424
Open AccessThe differential diagnosis of constitutional delay of puberty and hypogonadotropic hypogonadism in boys
Backgraund: The problem of differential diagnosis of constitutional delay of puberty/CPD and hypogonadotropic hypogonadism/HH in boys is discussed, as boys have similar genetic mechanisms and appearance. Aims: to determine accuracy of the criteria for the differential diagnosis of CDP and HH. Materials: The study included 56 boys14,40,7 years old with delayed puberty (G1P1-3/testicular volume 3сm3). We excluded patients with hypergonadotropic hypogonadism, treated with sex steroids or gonadotropins for 12 months, with endocrine/somatic diseases affecting puberty. At the first visit, we evaluated anthropometric data, bone age, testicular volume, hormones and the results of the gonadotropin-releasing hormone test/GnRH agonist test and the human chorionic gonadotropin test/hCG test. The HH was defined by a testicular volume 3сm3 after 2 years follow-up. The patients were divided into two groups: the first group with CDP and testicles 3cm3 (n=50) and the second group with HH and testicles 3cm3 (n=6). Results: At the first visit in boys with CDP corrected target height was less (Me SDS -1,8 vs -0,4, р=0,02), bone age was less (Ме SDS -2,5 vs - 0,2 р=0,03), testicular volume was more (Ме 1,9 vs 0,5, p=0,0003), hormones were significantly higher, such as, LH (Ме 1,1 vs 0,1mIU/ml, p=0,0002), FSH (Ме 1,9 vs 0,2IU/l, p=0,00007), inhibinB (Ме 142,3 vs 31,3pg/ml, p=0,00009), maxLH (Ме 18,9 vs 0,6mIU/ml, p=0,00007), maxLH/FSH (Ме 2,3 vs 0,4, p=0,0002) on the GnRH agonist test and testosterone (Ме 14,4 vs 1,1nmol/l, p=0,0001) on the hCG test than in boys with HH. The LH 0,3 mIU/ml had 86% sensitivity, 100% specificity; maxLH/FSH1- 92% sensitivity, 100% specificity; testosterone 2,7 nmol/l on the hCG test - 98% sensitivity, 100% specificity for differential diagnosis of CDP and HH in boys. However, maxLH 3,5 mIU/ml on the GnRH agonist test, FSH 0,5 IU/l, inhibinB 58 pg/ml had 100% sensitivity and specificity for diagnosis of CDP. Conclusions: The inhibinB 58 pg/ml, LH 0,3 mIU/ml, FSH 0,5 IU/l or maxLH 3,5 mIU/ml, maxLH/FSH 1,0 on the GnRH agonist test, testosterone 2,7 nmol/l on the hCG test have an excellent accuracy for the differential diagnosis of CDP and HH in prepubertal boys with delayed puberty.
- Open Access
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 103-105
Growth and sexual retardation in a boy with celiac disease
Growth and sexual retardation in boys can be caused by both endocrine and somatogenic causes. One of the somatogenic causes of growth and puberty retardation is celiac disease that is a genetic disorder of the small intestine, which is associated with deficiency of enzymes breaking down the gluten peptide. The clinical picture of celiac disease may be dominated by gastrointestinal manifestations (diarrhea, recurrent abdominal pain, nausea, constipation, appetite disorders) and nonspecific symptoms (irritability, apathy, physical and sexual retardation, impaired reproductive function, anemia, etc.). We present a case of late diagnosis of celiac disease in a 15-year-old boy with physical (height SDS, -4.1; bone age SDS, -8.2) and sexual (Tanner 1) retardation. The negative results of gonadoliberin (max LH, 2 mIU/mL) and chorionic gonadotropin (Δ-testosterone, 2,3 nmol/L) tests indicated the lack of activation of the hypothalamo-pituitary-gonadal system. However, inhibin B (29.9 pg/mL) and anti-Mullerian hormone (43.8 ng/mL) levels indicated preservation of the reserve capabilities of this system. During follow-up, after treatment with a gluten-free diet for 10 months, the patient demonstrated an improved growth rate (2.7 SDS), progression of the sexual development stage (Tanner 2), and positive results of diagnostic diphereline (max LH, 16.8 IU/mL) and chorionic gonadotropin (Δ-testosterone, 11.8 nmol/L) tests. This case demonstrates the need to exclude celiac disease in patients with growth and sexual retardation, especially when these pathologies are combined with protein-energy deficiency, gastrointestinal symptoms, and anemia, as well as the need to use additional indicators of the reproductive system condition in boys, e.g. inhibin B and anti-Mullerian hormone.
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 103-105
Open AccessGrowth and sexual retardation in a boy with celiac disease
Growth and sexual retardation in boys can be caused by both endocrine and somatogenic causes. One of the somatogenic causes of growth and puberty retardation is celiac disease that is a genetic disorder of the small intestine, which is associated with deficiency of enzymes breaking down the gluten peptide. The clinical picture of celiac disease may be dominated by gastrointestinal manifestations (diarrhea, recurrent abdominal pain, nausea, constipation, appetite disorders) and nonspecific symptoms (irritability, apathy, physical and sexual retardation, impaired reproductive function, anemia, etc.). We present a case of late diagnosis of celiac disease in a 15-year-old boy with physical (height SDS, -4.1; bone age SDS, -8.2) and sexual (Tanner 1) retardation. The negative results of gonadoliberin (max LH, 2 mIU/mL) and chorionic gonadotropin (Δ-testosterone, 2,3 nmol/L) tests indicated the lack of activation of the hypothalamo-pituitary-gonadal system. However, inhibin B (29.9 pg/mL) and anti-Mullerian hormone (43.8 ng/mL) levels indicated preservation of the reserve capabilities of this system. During follow-up, after treatment with a gluten-free diet for 10 months, the patient demonstrated an improved growth rate (2.7 SDS), progression of the sexual development stage (Tanner 2), and positive results of diagnostic diphereline (max LH, 16.8 IU/mL) and chorionic gonadotropin (Δ-testosterone, 11.8 nmol/L) tests. This case demonstrates the need to exclude celiac disease in patients with growth and sexual retardation, especially when these pathologies are combined with protein-energy deficiency, gastrointestinal symptoms, and anemia, as well as the need to use additional indicators of the reproductive system condition in boys, e.g. inhibin B and anti-Mullerian hormone.